Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pemigatinib

FDA-approved product (tablet, oral), marketed as Pemazyre.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Pemigatinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Cholangiocarcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fibroblast growth factor receptor (fgfr) tyrosine kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli56.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pemigatinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pemigatinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

    NCT04088188 · start 2021-01-25

    Registered record
    Registry ID
    NCT04088188
    Conditions
    Advanced Cholangiocarcinoma; Metastatic Cholangiocarcinoma; Unresectable Cholangiocarcinoma
    Interventions
    Cisplatin; Gemcitabine; Ivosidenib; Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2021-01-25
    Completion
    2023-12-01
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cholangiocarcinoma; Metastatic Cholangiocarcinoma; Unresectable Cholangiocarcinoma
    InterventionCisplatin; Gemcitabine; Ivosidenib; Pemigatinib
    PhasePhase 1
    Registry statusTerminated

  • Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

    NCT04659616 · start 2021-01-14

    Registered record
    Registry ID
    NCT04659616
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Biospecimen Collection; Bone Marrow Aspirate; Bone Marrow Biopsy; Cytarabine; Daunorubicin; Electrocardiography; Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2021-01-14
    Completion
    2026-12-31
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionBiospecimen Collection; Bone Marrow Aspirate; Bone Marrow Biopsy; Cytarabine +3 more
    PhasePhase 1
    Registry statusRecruiting

  • The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

    NCT04591431 · start 2020-10-07

    Registered record
    Registry ID
    NCT04591431
    Conditions
    Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer; Other Cancer
    Interventions
    Erlotinib; Trastuzumab; Trastuzumab emtansine; Pertuzumab; Lapatinib; Everolimus; Vemurafenib; Cobimetinib; Alectinib; Brigatinib; Palbociclib; Ponatinib; Vismogedib; Itacitinib; Ipatasertib; Entrectinib; Atezolizumab; Nivolumab; Ipilimumab; Pemigatinib; Oncology Drugs; Pralsetinib; Selpercatinib; Talazoparib; Tepotinib; Alpelisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-10-07
    Completion
    2025-06
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer; Other Cancer
    InterventionErlotinib; Trastuzumab; Trastuzumab emtansine; Pertuzumab +22 more
    PhasePhase 2
    Registry statusUnknown

  • A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

    NCT03914794 · start 2020-10-02

    Registered record
    Registry ID
    NCT03914794
    Conditions
    Bladder Cancer; NMIBC; Non-Muscle Invasive Bladder Cancer; Urothelial Carcinoma Recurrent
    Interventions
    Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-10-02
    Completion
    2025-09-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBladder Cancer; NMIBC; Non-Muscle Invasive Bladder Cancer; Urothelial Carcinoma Recurrent
    InterventionPemigatinib
    PhasePhase 2
    Registry statusCompleted

  • Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

    NCT04096417 · start 2020-08-31

    Registered record
    Registry ID
    NCT04096417
    Conditions
    FGFR1 Gene Amplification; FGFR1 Gene Mutation; FGFR1 Gene Translocation; FGFR2 Gene Amplification; FGFR2 Gene Mutation; FGFR2 Gene Translocation; FGFR3 Gene Amplification; FGFR3 Gene Mutation; FGFR3 Gene Translocation; Metastatic Colorectal Carcinoma; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Unresectable Colorectal Carcinoma
    Interventions
    Pemigatinib; Quality-of-Life Assessment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-08-31
    Completion
    2025-12-01
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFGFR1 Gene Amplification; FGFR1 Gene Mutation; FGFR1 Gene Translocation; FGFR2 Gene Amplification +15 more
    InterventionPemigatinib; Quality-of-Life Assessment
    PhasePhase 2
    Registry statusUnknown

  • Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery

    NCT04294277 · start 2020-07-13

    Registered record
    Registry ID
    NCT04294277
    Conditions
    Urothelial Cancer
    Interventions
    Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-07-13
    Completion
    2022-11-15
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrothelial Cancer
    InterventionPemigatinib
    PhasePhase 2
    Registry statusTerminated

  • Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

    NCT04003610 · start 2020-05-14

    Registered record
    Registry ID
    NCT04003610
    Conditions
    Metastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma
    Interventions
    Pemigatinib; Pembrolizumab; Gemcitabine; Carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-05-14
    Completion
    2021-04-18
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma
    InterventionPemigatinib; Pembrolizumab; Gemcitabine; Carboplatin
    PhasePhase 2
    Registry statusTerminated

  • Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations

    NCT04258527 · start 2020-03-26

    Registered record
    Registry ID
    NCT04258527
    Conditions
    Solid Tumor
    Interventions
    Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-03-26
    Completion
    2021-03-08
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor
    InterventionPemigatinib
    PhasePhase 1
    Registry statusCompleted

  • Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement

    NCT04256980 · start 2020-03-03

    Registered record
    Registry ID
    NCT04256980
    Conditions
    Cholangiocarcinoma
    Interventions
    Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-03-03
    Completion
    2023-08-31
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCholangiocarcinoma
    InterventionPemigatinib
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

    NCT04003623 · start 2019-10-31

    Registered record
    Registry ID
    NCT04003623
    Conditions
    Advanced or Metastatic Solid Tumors; FGFR Mutations; FGFR Translocations
    Interventions
    Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-10-31
    Completion
    2020-06-12
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced or Metastatic Solid Tumors; FGFR Mutations; FGFR Translocations
    InterventionPemigatinib
    PhasePhase 2
    Registry statusTerminated

  • Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

    NCT03822117 · start 2019-10-17

    Registered record
    Registry ID
    NCT03822117
    Conditions
    Solid Tumor Malignancy
    Interventions
    Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-10-17
    Completion
    2022-03-29
    Enrolment
    111

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor Malignancy
    InterventionPemigatinib
    PhasePhase 2
    Registry statusTerminated

  • Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.

    NCT05529667 · start 2019-05-27

    Registered record
    Registry ID
    NCT05529667
    Conditions
    Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel
    Interventions
    INCB054828, Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2019-05-27
    Completion
    2023-08-30
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel
    InterventionINCB054828, Paclitaxel
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

    NCT03498521 · start 2018-07-10

    Registered record
    Registry ID
    NCT03498521
    Conditions
    Cancer of Unknown Primary Site
    Interventions
    Alectinib; Vismodegib; Ipatasertib; Olaparib; Erlotinib; Bevacizumab; Vemurafenib; Cobimetinib; Trastuzumab Subcutaneous (SC); Pertuzumab; Atezolizumab; Carboplatin; Paclitaxel; Cisplatin; Gemcitabine; Entrectinib; Ivosidenib; Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-07-10
    Completion
    2024-11-07
    Enrolment
    529

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer of Unknown Primary Site
    InterventionAlectinib; Vismodegib; Ipatasertib; Olaparib +14 more
    PhasePhase 2
    Registry statusCompleted

  • A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)

    NCT03235570 · start 2017-08-01

    Registered record
    Registry ID
    NCT03235570
    Conditions
    Solid Tumors
    Interventions
    Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-08-01
    Completion
    2020-03-04
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors
    InterventionPemigatinib
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

    NCT03011372 · start 2017-04-25

    Registered record
    Registry ID
    NCT03011372
    Conditions
    MPN (Myeloproliferative Neoplasms)
    Interventions
    Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-04-25
    Completion
    2024-10-30
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMPN (Myeloproliferative Neoplasms)
    InterventionPemigatinib
    PhasePhase 2
    Registry statusCompleted